MedNexus
2022年 · 第135卷第24期
出版日期 2022-12-20电子版 ￥0.00元
MedNexus
- 全部
- Clinical Guideline
- Consensus Statement
- Review Article
- Perspective
- Original Article
- Correspondence
- Corrigendum
Clinical Guideline
开放获取
2022年中国国家临床实践指南幽门螺杆菌根除治疗Liya Zhou, Hong Lu, Zhiqiang Song, Bin Lyu, Ye Chen, Jiyao Wang, Jun Xia, Zhan Zhao
中华医学杂志英文版2022年 135卷 24期
DOI: 10.1097/CM9.0000000000002546
摘要
Background:
Helicobacter pylori (H. pylori) infection is an infectious disease with a prevalence rate of up to 50% worldwide. It can cause indigestion, gastritis, peptic ulcer, and gastric cancer. H. pylori eradication treatment can effectively control disease progression and reduce the risk of the above conditions. However, the escalating trend of antibiotic resistance presents a global challenge for H. pylori eradication. We aim to provide guidance on pharmacological treatment of H. pylori infection.
Methods:
This clinical practice guideline is developed following the World Health Organization’s recommended process, adopting Grading of Recommendations Assessment, Development and Evaluation in assessing evidence quality, and utilizing Evidence to Decision framework to formulate clinical recommendations, minimizing bias and increasing transparency of the clinical practice guideline development process. We used the Reporting Items for practice Guidelines in HealThcare (RIGHT) statement and The Appraisal of Guidelines for Research and Evaluation II (AGREE II) as reporting and conduct guides to ensure the guideline’s completeness and transparency.
Results:
Though decreasing in developed countries, the prevalence of H. pylori remains high in developing countries, causing a major public health burden. This clinical practice guideline contains 12 recommendations concerning pharmacological treatment for H. pylori eradication. Among them, it is worth highlighting that bismuth preparations are inexpensive, safe, and effective, consequently making bismuth quadruple therapy a preferred choice for initial and rescue treatment. In empirical treatment, high-dose dual therapy is equally effective compared with bismuth quadruple therapy.
Conclusions:
The 12 recommendations in this clinical practice guideline are formed with consideration for stakeholders’ values and preferences, resource use, feasibility, and acceptability. Recommendations are generalizable to resource limited settings with similar antibiotic resistance pattern as China, and lower middle-income countries facing comparable sociological and technical challenges.
Registration:
Guidelines International Network (GIN) website, https://guidelines.ebmportal.com/node/69996.
Consensus Statement
开放获取
中国肝细胞癌肝移植临床实践指南（2021版）Jun Chen, Tian Shen, Jianhui Li, Sunbin Ling, Zhe Yang, Guoying Wang, Liying Sun, Zhaoxu Yang, Li Zhuang, Jie Gao 等
中华医学杂志英文版2022年 135卷 24期
DOI: 10.1097/CM9.0000000000002515
摘要
肝细胞癌（HCC）是中国60岁以下成年男性癌症相关死亡的主要原因。[
Review Article
开放获取
弥漫性胶质瘤的分子病理学及临床意义Ruichao Chai, Shengyu Fang, Bo Pang, Yuqing Liu, Yongzhi Wang, Wei Zhang, Tao Jiang
中华医学杂志英文版2022年 135卷 24期
DOI: 10.1097/CM9.0000000000002446
摘要
The prognosis for diffusely infiltrating gliomas at World Health Organization (WHO) grade 2-4 remains dismal due to their heterogeneity. The rapid development of genome-wide molecular-profiling-associated studies has greatly promoted the accuracy of glioma classification. Thus, the latest version of the WHO classification of the central nervous system tumors published in 2021 has incorporated more molecular biomarkers together with histological features for the diagnosis of gliomas. Advanced usage of molecular pathology in clinical diagnostic practice provides also new opportunities for the therapy of patients with glioma, including surgery, radiotherapy and chemotherapy, targeted therapy, immunotherapy, and more precision clinical trials. Herein, we highlight the updates in the classification of gliomas according to the latest WHO guidelines and summarize the clinically relevant molecular markers by focusing on their applications in clinical practice. We also review the advances in molecular features of gliomas, which can facilitate the development of glioma therapies, thereby discussing the challenges and future directions of molecular pathology toward precision medicine for patients with glioma.
开放获取
全球肾脏去神经化不同共识文件之间的共识和不一致：前进的方向Tzung-Dau Wang
中华医学杂志英文版2022年 135卷 24期
DOI: 10.1097/CM9.0000000000002109
摘要
Given the unsatisfactory hypertension control rates and high rates of non-adherence to antihypertensive medications worldwide, device therapy which can safely provide durable blood pressure-lowering effects can fulfill the unmet need. A series of second-generation randomized sham-controlled renal denervation (RDN) trials have demonstrated the efficacy and safety of RDN in a wide range of hypertensive patients. The four representative consensus documents on RDN (from the Chinese Taiwan Hypertension Society and Taiwan Society of Cardiology [THS/TSOC 2019], Asia Renal Denervation Consortium 2019, European Society of Hypertension [ESH 2021], and Society for Cardiovascular Angiography & Intervention and National Kidney Foundation [SCAI/NKF 2021]) consistently recommend RDN as an alternative or complementary treatment strategy for patients with uncontrolled hypertension. In addition, both documents from Asia further recommend that RDN can be considered as an initial treatment strategy for drug-naïve hypertensive patients. There is still inconsistency regarding whether ambulatory blood pressure monitoring should be used routinely both before and after RDN, and whether patients with a secondary cause of hypertension could be treated with RDN if their blood pressure remains uncontrolled after definitive treatment (treatment-resistant secondary hypertension). The THS/TSOC consensus provides acronyms to summarize key aspects of patient selection (RDNi2) and pre-RDN assessments (RAS). The ESH and SCAI/NKF documents recommend establishing structured pathways for clinical practice and issues regarding reimbursement. All documents identify knowledge gaps in RDN, from identifying predictors of super-responders to demonstrating effects on cardiovascular events. These gaps should be urgently filled to facilitate the wider application of this device therapy for patients with hypertension.
Perspective
开放获取
复杂腹腔镜脾脏手术的出血控制：现状与挑战Nan You, Jing Li, Lu Zheng
中华医学杂志英文版2022年 135卷 24期
DOI: 10.1097/CM9.0000000000002293
摘要
严重的术中出血限制了复杂腹腔镜脾切除术（LS）的应用，包括腹腔镜全脾切除术（LTS）和腹腔镜脾部分切除术（LPS）。因此，降低复杂LS的出血风险已成为人们感兴趣的主要课题【补充图1，http://links.lww.com/CM9/B377】。
Original Article
开放获取
阿那拉唑治疗十二指肠溃疡的疗效和安全性：一项随机、雷贝拉唑对照、III期非劣效性研究Huiyun Zhu, Xue Pan, Li Zhang, Hongxin Sun, Huizhen Fan, Zhongwei Pan, Caibin Huang, Zhenwang Shi, Jin Ding, Qi Wang 等
中华医学杂志英文版2022年 135卷 24期
DOI: 10.1097/CM9.0000000000002508
摘要
Background:
The pharmacokinetic and clinical behaviors of many proton pump inhibitors (PPIs) in peptic ulcer treatment are altered by CYP2C19 genetic polymorphisms. This non-inferiority study evaluated the efficacy and safety of the novel PPI anaprazole compared with rabeprazole. We also explored the influence of Helicobacter pylori (H. pylori) infection status and CYP2C19 polymorphism on anaprazole.
Methods:
In this multicenter, randomized, double-blind, double-dummy, positive-drug parallel-controlled, phase III study, Chinese patients with duodenal ulcers were randomized 1:1 to receive rabeprazole 10 mg + anaprazole placebo or rabeprazole placebo + anaprazole 20 mg once daily for 4 weeks. The primary efficacy endpoint was the 4-week ulcer healing rate assessed by blinded independent review. Secondary endpoints were the proportion of patients with improved overall and individual duodenal ulcer symptoms at 4 weeks. Furthermore, exploratory subgroup analysis of the primary endpoint by H. pylori status and CYP2C19 polymorphism was conducted. Adverse events were monitored for safety. Non-inferiority analysis was conducted for the primary endpoint.
Results:
The study enrolled 448 patients (anaprazole, n = 225; rabeprazole, n = 223). The 4-week healing rates were 90.9% and 93.7% for anaprazole and rabeprazole, respectively (difference, -2.8% [95% confidence interval, -7.7%, 2.2%]), demonstrating non-inferiority of anaprazole to rabeprazole. Overall duodenal ulcer symptoms improved in 90.9% and 92.5% of patients, respectively. Improvement rates of individual symptoms were similar between the groups. Healing rates did not significantly differ by H. pylori status or CYP2C19 genotype for either treatment group. The incidence of treatment-emergent adverse events was similar for anaprazole (72/220, 32.7%) and rabeprazole (84/219, 38.4%).
Conclusions:
The efficacy of anaprazole is non-inferior to that of rabeprazole in Chinese patients with duodenal ulcers.
Registration:
ClinicalTrials.gov, NCT04215653.
开放获取
残疾调整生命年和结直肠癌负担趋势：2002-2016年中国上海一项基于人群的研究Wei Zhong, Liping Chen, Xiaopan Li, Yichen Chen, Yao Zhang, Canjie Guo, Yufeng Shen, Huimin Chen
中华医学杂志英文版2022年 135卷 24期
DOI: 10.1097/CM9.0000000000002064
摘要
Background:
Colorectal cancer (CRC) still ranks the top in morbidity and mortality of cancers worldwide, posing a huge threat and burden to the society. We aimed to determine the age-standardized incidence, mortality, and disability-adjusted life years (DALYs) of CRC and explore potential changes in the temporal trends of the CRC burden in Shanghai during 2002 to 2016.
Methods:
The cancer statistics and demographics were obtained from the Cancer Registry and the Statistics Bureau of Pudong New Area, respectively. Data from 2002 to 2016 were included and analyzed retrospectively. DALYs were calculated using DisMod and the age-standardized rates (ASRs) were obtained according to Segi world standard population. Joinpoint regression was used to measure the trends in CRC incidence and to estimate the annual percent change.
Results:
The increasing trend of CRC ASR incidence halted after 2014, coinciding with the introduction of the Shanghai CRC screening program. The ASRs of mortality and DALYs increased, at 0.42% (P < 0.05) and 4.07% (P < 0.001) per year, respectively, which were mainly driven by men and individuals aged above the CRC screening program target.
Conclusions:
The disease burden of CRC in Shanghai remains serious, especially among men, and individuals aged >74 years. The benefits of the screening program have been partially proven by the ASRs of CRC incidence, providing important insights into better and wider application of screening programs.
开放获取
L-岩藻糖通过引起microRNA-200b过表达抑制胆管癌的进展Biqiang Zhu, Jingjing Zheng, Gaichao Hong, Tao Bai, Wei Qian, Jinsong Liu, Xiaohua Hou
中华医学杂志英文版2022年 135卷 24期
DOI: 10.1097/CM9.0000000000002368
摘要
Background:
Cholangiocarcinoma (CCA) is a malignant biliary tract tumor with an extremely poor prognosis. There is an urgent demand to explore novel therapeutic strategies. L-fucose has been confirmed to participate in anti-inflammation and antitumor activities. However, the effect of L-fucose on the progression of CCA has not been well investigated. This study aimed to determine whether L-fucose induced the inhibition of CCA and its possible mechanism.
Methods:
The anti-growth activity was determined using Cell Counting Kit-8 assay, colony formation assays, Annexin V-fluorescein isothiocyanate/propidium iodide (FITC/PI) assay, and cell cycle analysis. The anti-metastasis activity was determined by wound healing, transwell, and invasion assays. The anti-angiogenesis activity was determined by tube formation and transwell assays. MicroRNAs that may be involved in the L-fucose-induced CCA inhibition was analyzed using bioinformatics methods. The preclinical therapeutic efficacy was mainly estimated by ultrasound in xenograft nude mouse models. Differences were analyzed via Student’s t test or one-way analysis of variance.
Results:
L-Fucose induced apoptosis and G0/G1 cell cycle arrest, inhibited cell epithelial-mesenchymal transition of CCA cells, and additionally inhibited tube formation of human umbilical vein endothelial cells (HUVECs) in a dose-dependent manner, leading to a decrease in cell proliferation, metastasis, and angiogenesis. Mechanistically, L-fucose induced microRNA-200b (miR-200b) upregulation, and mitogen-activated protein kinase 7 (MAPK7) downregulation was found to be targeted by miR-200b, with decreased cell proliferation and metastasis. Additionally, phosphorylated signal transducer and activator of transcription 3 was found to be downregulated after L-fucose treatment. Finally, in vivo experiments in CCA xenograft models also confirmed the antitumor properties of L-fucose.
Conclusion:
L-Fucose inhibited the progression of CCA via the miR-200b/MAPK7 and signal transducer and activator of transcription 3 signaling pathways.
开放获取
中国主动脉瓣狭窄患者主动脉瓣的解剖形态及经导管主动脉瓣置换术缩小策略后的临床结果Guannan Niu, Walid Ben Ali, Moyang Wang, Hasan Jilaihawi, Haitong Zhang, Qian Zhang, Yunqing Ye, Xinmin Liu, Jing Yao, Qinghao Zhao 等
中华医学杂志英文版2022年 135卷 24期
DOI: 10.1097/CM9.0000000000002517
摘要
Background:
The study aimed to describe the aortic valve morphology in Chinese patients underwent transcatheter aortic valve replacement (TAVR) for symptomatic severe aortic stenosis (AS), and the impact of sizing strategies and related procedural outcomes.
Methods:
Patients with severe AS who underwent TAVR were consecutively enrolled from 2012 to 2019. The anatomy and morphology of the aortic root were assessed. "Downsize" strategy was preformed when patients had complex morphology. The clinical outcomes of patients who performed downsize strategy were compared with those received annular sizing strategy. The primary outcome was device success rate, and secondary outcomes included Valve Academic Research Consortium-3 clinical outcomes variables based on 1-year follow-up.
Results:
A total of 293 patients were enrolled. Among them, 95 patients (32.4%) had bicuspid aortic valve. The calcium volume (Hounsfield Unit-850) of aortic root was 449.90 (243.15-782.15) mm3. Calcium is distributed mostly on the leaflet level. Downsize strategy was performed in 204 patients (69.6%). Compared with the patients who performed annular sizing strategy, those received downsize strategy achieved a similar device success rate (82.0% [73] vs. 83.3% [170], P= 0.79). Aortic valve gradients (downsize strategy group vs. annular sizing group, 11.28 mmHg vs. 11.88 mmHg, P = 0.64) and percentages of patients with moderate or severe paravalvular regurgitation 2.0% (4/204) vs. 4.5% (4/89), P = 0.21) were similar in the two groups at 30 days after TAVR. These echocardiographic results were sustainable for one year.
Conclusions:
Chinese TAVR patients have more prevalent bicuspid morphology and large calcium volume of aortic root. Calcium is distributed mostly on the leaflet level. Compare with annular sizing strategy, downsize strategy provided a non-inferior device success rate and transcatheter heart valve hemodynamic performance in self-expanding TAVR procedure.
开放获取
中国≥80岁成人低镉汞暴露与慢性肾脏病关系的横断面研究Yuan Wei, Yuebin Lyu, Zhaojin Cao, Feng Zhao, Yingchun Liu, Chen Chen, Chengcheng Li, Heng Gu, Feng Lu, Jinhui Zhou 等
中华医学杂志英文版2022年 135卷 24期
DOI: 10.1097/CM9.0000000000002395
摘要
Background:
The heavy metals cadmium (Cd) and mercury (Hg) are known to be widespread environmental contaminants and high occupational exposure adversely affects the risk of chronic kidney disease (CKD). However, evidence from epidemiological studies linking low Cd and Hg exposure (or non-industrial) to the risk of progression to CKD are conflicting. This study aimed to explore the association of low Cd and Hg exposure with the risk of CKD in Chinese adults aged ≥80 years.
Methods:
The participants were recruited for the Healthy Aging and Biomarkers Cohort Study in 2017, an ongoing perspective survey conducted in longevity areas in China initially involving 3016 older adults. We used logistic regression models to estimate odds ratios (ORs) with 95% confidence intervals of CKD setting Cd and Hg as categorical variables. Logistic regression with restricted cubic spline was used to characterize a dose-response relationships between Cd or Hg concentrations and the risk of CKD in the study population.
Results:
The ORs for the risk of CKD comparing the fourth to the first quartile of blood Cd, blood Hg, urine Cd, and urine Hg were 1.77, 1.57, 2.03, and 1.50, respectively. Restricted cubic spline models showed that blood Cd and urine Hg were significantly linearly correlated with the risk of CKD, while blood Hg and urine Cd were non-linearly correlated with the risk of CKD with a steeper slope at concentrations <2.30 μg/L and 3.30 μg/g creatinine.
Conclusions:
Our findings suggest that even low Cd and Hg exposure (or non-industrial) were associated with increased risk of CKD in Chinese oldest old, although we did not find a significant multiplicative and additive interaction between Cd and Hg levels in relation to the risk of CKD.
开放获取
基于社会决定因素和危险因素的中国尘肺患者肺结核流行病学特征：来自27个省份的横断面研究Huanqiang Wang, Huaping Dai, Jiayu He, Xiangpei Lyu, Xinran Zhang, Tao Li
中华医学杂志英文版2022年 135卷 24期
DOI: 10.1097/CM9.0000000000002486
摘要
Background:
Patients with pneumoconiosis have an elevated risk of contracting pulmonary tuberculosis (PTB) and need particular attention. However, extensive population-based studies on the prevalence of PTB in patients with pneumoconiosis have not been reported in China since 1992. This study aimed to investigate the epidemiological characteristics of PTB in patients with pneumoconiosis based on its social determinants and risk factors in China.
Methods:
Based on the Commission on Social Determinants of Health (CSDH) framework, data were obtained from a questionnaire survey of patients with pneumoconiosis from China’s 27 provinces (autonomous regions, municipalities) from December 2017 to June 2021. By chi-square and multivariate logistic regression analyses, the epidemiological characteristics of PTB in the patients were identified based on its prevalence and odds ratio (OR) and associated social determinants and risk factors. The population attributable fractions (PAFs) of significant risk factors were also calculated.
Results:
The prevalence of PTB in patients with pneumoconiosis (n = 10,137) was 7.5% (95% confidence interval [CI]: 7.0-8.0%). Multivariate logistic regression analysis showed that risk factors included in-hospital exposure to patients with PTB (OR = 3.30, 95% CI: 2.77-3.93), clinically diagnosed cases (OR = 3.25, 95% CI: 2.42-4.34), and northeastern regions (OR = 2.41, 95% CI: 1.76-3.31). In addition, lack of work-related injury insurance (WRII), being born in a rural area, being unemployed, living in western regions, household exposure to patients with PTB, smoking, being underweight, complications of pulmonary bullae or pneumothorax, hospitalization history, and former drinkers among the rural patients were also statistically significant risk factors. Being born in a rural area, lack of WRII and in-hospital exposure to patients with PTB had higher PAFs, which were 13.2% (95% CI: 7.9-18.5%), 12.5% (95% CI: 8.3-16.7%), and 11.6% (95% CI: 8.8-14.3%), respectively.
Conclusion:
The prevalence of PTB in pneumoconiosis remains high in China; it is basically in line with the CSDH models and has its characteristics.
Correspondence
开放获取
狮身人面像之谜：关于精神压力与肿瘤发生发展之间联系的事实和证据Ruilin Wang, Sheng Yu, Limeng Yu, Qiming Wang, Yufeng Wu
中华医学杂志英文版2022年 135卷 24期
DOI: 10.1097/CM9.0000000000002129
摘要
致编辑：“狮身人面像之谜”的答案是“人”，人的形象既有消极的一面，也有积极的一面。它经常被用来比喻复杂、神秘和不可理解的问题。随着现代生活环境的恶化和应激的加重，肿瘤的发病率呈上升趋势。过度或长期的应激可导致急性或慢性器官功能障碍和代谢紊乱。研究表明，肿瘤患者往往处于长期的不良应激状态。慢性精神应激通过激活体内应激相关的转录调节因子和信号通路来改变肿瘤细胞的存活、增殖和转移。随着它们在应激下肿瘤发展中的重要作用的证明，相关途径或细胞因子可以被拮抗或抑制以改变肿瘤发展的轨迹。本文探讨了慢性精神应激如何通过影响脑源性神经营养因子的表达来影响肿瘤细胞的存在（BDNF）、胰岛素样生长因子2/胰岛素样生长因子1受体（IGF2/IGF1R）、C反应蛋白（CRP）等癌症患者的可能途径。
开放获取
关节镜治疗外侧上髁痛从囊内到囊外的进展Yuping Yang, Shuo Yuan, Hongling Chu, Hui Yan, Jian Xiao, Xu Cheng, Hao Luo, Yulei Liu, Liyuan Tao, Yiming Zhao 等
中华医学杂志英文版2022年 135卷 24期
DOI: 10.1097/CM9.0000000000002204
摘要
致编辑：外上髁痛，其发生率约为1.3%，不仅发生在网球运动员身上（网球运动员仅占5%[
开放获取
一种新的抗转移提取物瑞香狼毒。通过抑制粘着斑激酶抑制乳腺肿瘤细胞运动Xinke Du, Li Liu, Lina Yang, Lidong Sun, Qingsen Ran, Ying Chen, Yujie Li, Qing Yang, Yajie Wang, Xiaogang Weng 等
中华医学杂志英文版2022年 135卷 24期
DOI: 10.1097/CM9.0000000000002311
摘要
致编辑：在乳腺癌中，是转移明确区分了生与死。[
开放获取
配方的环硅酸锆钠预处理体外减少慢性肾病婴儿的钾摄入量Boxuan Liu, Teng Wang, Zhi Chen
中华医学杂志英文版2022年 135卷 24期
DOI: 10.1097/CM9.0000000000002461
摘要
致编辑：高钾血症是婴儿晚期慢性肾脏病（CKD）常见的危及生命的并发症。为了控制高钾血症，饮食钾摄入限制是最方便、安全和有效的治疗方法。肾脏疾病结局质量倡议（KDOQI）指南建议一般限钾为40~120 mg·kg-1·日-1对于婴儿和30至40 mg·kg-1·日-1对于患有慢性肾病的年龄较大的儿童。[
开放获取
计算机辅助诊断先天性心脏病在胎心基础筛查四腔视图中的应用Fangfei Su, Xiaoqian Zhang, Jijing Han, Jingjing Wang, Lu Li, Dexing Kong, Qingqing Wu
中华医学杂志英文版2022年 135卷 24期
DOI: 10.1097/CM9.0000000000002274
摘要
致编辑：C先天性心脏病（CHD）是最常见的严重先天性畸形，威胁胎儿健康，是胎儿宫内死亡的主要原因。严重冠心病的产前检测可降低新生儿死亡率和发病率。产前超声检查检出率为25.0%~59.7%。[
开放获取
中国成年人血浆致动脉粥样硬化指数的特点及参考值Yuelun Zhang, Yunying Feng, Shi Chen, Hanze Du, Huijuan Zhu, Hui Pan, Guangliang Shan
中华医学杂志英文版2022年 135卷 24期
DOI: 10.1097/CM9.0000000000002182
摘要
致编辑：血浆致动脉粥样硬化指数(AIP)由甘油三酯(TG)与高密度脂蛋白胆固醇(HDL-C)的比率的对数转换得出。综合反映血浆脂质稳态。据报道，在基于人群的研究中，AIP与心血管疾病（CVD）有关，[
开放获取
急性肾损伤患者的社会经济差异：一项全国性调查对中国地方医院的亚组分析Lihua Wu, Jinwei Wang, Yaqi Ma, Fengwu Luan, Mengting Wang, Zhihong Feng, Yanhong Tian, Lu Li, Rui Chu, Xiaolong Yin 等
中华医学杂志英文版2022年 135卷 24期
DOI: 10.1097/CM9.0000000000002330
摘要
致编辑：急性肾损伤（AKI）是世界范围内常见的公共卫生问题，可对患者的生活质量产生不利影响，甚至导致死亡。[
开放获取
儿童不明原因急性重型肝炎的临床特点及可能病因Jie Li, Xinyu Hu, Xuebing Yan, Chao Wu, Yuemin Nan
中华医学杂志英文版2022年 135卷 24期
DOI: 10.1097/CM9.0000000000002445
摘要
致编辑：根据世界卫生组织（WHO）2022年7月12日发布的数据，全球已有5个地区和35个国家报告了约1010例病因不明的儿童急性肝炎病例；这些报告包括自2021年10月1日以来的新病例和回顾性发现的病例。大多数患者表现为急性重型肝炎和转氨酶水平显著升高；最常见的症状和体征是恶心或呕吐（60%）、黄疸（53%）、全身无力（52%）和腹痛（50%），这些都是急性重型肝炎的典型症状。在可能的情况下，5%（n=46）的儿童需要移植，而2%（n=22)的死亡报告给世卫组织。[
开放获取
超微创手术和近端胃切除术治疗早期食管胃结合部腺癌后的健康相关生活质量：一项倾向评分匹配研究Mingming Meng, Ningli Chai, Shengzhen Liu, Xiuxue Feng, Enqiang Linghu
中华医学杂志英文版2022年 135卷 24期
DOI: 10.1097/CM9.0000000000002410
摘要
致编辑：近端胃切除术（PG）是早期食管胃结合部腺癌（AEG）的传统治疗方法。内镜黏膜下剥离术（ESD）和内镜黏膜下隧道剥离术（ESTD）新概念的超级微创手术（SMIS）具有与传统手术相同的疗效，优点是不在解剖学上改变消化道。[
Corrigendum
开放获取
勘误表：拓扑异构酶II α通过激活磷脂酰肌醇3-激酶/蛋白激酶B/雷帕霉素信号通路的哺乳动物靶点促进胆囊癌增殖和转移中华医学杂志英文版2022年 135卷 24期
DOI: 10.3760/cma.j.issn.0366-6999.2022.24.101
摘要
在最初的文章发表之后，[
本期目次
下载本期封面 下载本期目录
